Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Phase 1 in Advanced Solid Tumors
NCT03251378Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Dec 2017
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of fruquintinib in solid tumor (advanced stage), metastatic colorectal cancer (mCRC) and breast cancer (7 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Number of Participants With Dose-limiting Toxicities, Number of Participants With Treatment-emergent Adverse Events and Serious TEAEs up to 29 months and 1 more. Started Dec 2017; status: completed.
02
Drugs
fruquintinib
03
Conditions
solid tumor (advanced stage)metastatic colorectal cancer (mCRC)breast cancer
Beyond the preview
Go deeper on NCT03251378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251378.